vs

Side-by-side financial comparison of Certara, Inc. (CERT) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

Certara, Inc. is the larger business by last-quarter revenue ($103.6M vs $57.3M, roughly 1.8× RHYTHM PHARMACEUTICALS, INC.). Certara, Inc. runs the higher net margin — -5.7% vs -83.0%, a 77.3% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 3.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 3.6%).

Certara is a global leader in biopharmaceutical software and consulting services, specializing in modeling, simulation, and regulatory science solutions. It serves pharmaceutical companies, biotech firms and healthcare stakeholders across all drug development stages, helping accelerate new therapy launches, lower R&D risks and cut overall development costs.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

CERT vs RYTM — Head-to-Head

Bigger by revenue
CERT
CERT
1.8× larger
CERT
$103.6M
$57.3M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+33.6% gap
RYTM
36.9%
3.3%
CERT
Higher net margin
CERT
CERT
77.3% more per $
CERT
-5.7%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
3.6%
CERT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CERT
CERT
RYTM
RYTM
Revenue
$103.6M
$57.3M
Net Profit
$-5.9M
$-47.5M
Gross Margin
91.6%
Operating Margin
0.8%
-82.2%
Net Margin
-5.7%
-83.0%
Revenue YoY
3.3%
36.9%
Net Profit YoY
-189.6%
-9.6%
EPS (diluted)
$-0.04
$-0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CERT
CERT
RYTM
RYTM
Q4 25
$103.6M
$57.3M
Q3 25
$104.6M
$51.3M
Q2 25
$104.6M
$48.5M
Q1 25
$106.0M
$32.7M
Q4 24
$100.4M
$41.8M
Q3 24
$94.8M
$33.3M
Q2 24
$93.3M
$29.1M
Q1 24
$96.7M
$26.0M
Net Profit
CERT
CERT
RYTM
RYTM
Q4 25
$-5.9M
$-47.5M
Q3 25
$1.5M
$-52.9M
Q2 25
$-2.0M
$-46.6M
Q1 25
$4.7M
$-49.5M
Q4 24
$6.6M
$-43.3M
Q3 24
$-1.4M
$-43.6M
Q2 24
$-12.6M
$-32.3M
Q1 24
$-4.7M
$-141.4M
Gross Margin
CERT
CERT
RYTM
RYTM
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Q1 24
89.2%
Operating Margin
CERT
CERT
RYTM
RYTM
Q4 25
0.8%
-82.2%
Q3 25
2.9%
-102.6%
Q2 25
9.1%
-93.4%
Q1 25
7.2%
-143.7%
Q4 24
6.0%
-98.6%
Q3 24
2.7%
-132.0%
Q2 24
-9.7%
-139.2%
Q1 24
-1.3%
-538.7%
Net Margin
CERT
CERT
RYTM
RYTM
Q4 25
-5.7%
-83.0%
Q3 25
1.5%
-103.1%
Q2 25
-1.9%
-96.1%
Q1 25
4.5%
-151.4%
Q4 24
6.6%
-103.6%
Q3 24
-1.4%
-131.2%
Q2 24
-13.5%
-110.9%
Q1 24
-4.8%
-544.4%
EPS (diluted)
CERT
CERT
RYTM
RYTM
Q4 25
$-0.04
$-0.73
Q3 25
$0.01
$-0.82
Q2 25
$-0.01
$-0.75
Q1 25
$0.03
$-0.81
Q4 24
$0.04
$-0.71
Q3 24
$-0.01
$-0.73
Q2 24
$-0.08
$-0.55
Q1 24
$-0.03
$-2.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CERT
CERT
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$189.4M
$388.9M
Total DebtLower is stronger
$293.1M
Stockholders' EquityBook value
$1.1B
$139.1M
Total Assets
$1.6B
$480.2M
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CERT
CERT
RYTM
RYTM
Q4 25
$189.4M
$388.9M
Q3 25
$172.7M
$416.1M
Q2 25
$162.3M
$291.0M
Q1 25
$179.1M
$314.5M
Q4 24
$179.2M
$320.6M
Q3 24
$233.0M
$298.4M
Q2 24
$224.6M
$319.1M
Q1 24
$224.8M
$201.2M
Total Debt
CERT
CERT
RYTM
RYTM
Q4 25
$293.1M
Q3 25
$293.5M
Q2 25
$294.2M
Q1 25
$294.8M
Q4 24
$295.4M
Q3 24
$296.1M
Q2 24
$296.7M
Q1 24
$290.8M
Stockholders' Equity
CERT
CERT
RYTM
RYTM
Q4 25
$1.1B
$139.1M
Q3 25
$1.1B
$148.8M
Q2 25
$1.1B
$-11.9M
Q1 25
$1.1B
$18.9M
Q4 24
$1.1B
$21.7M
Q3 24
$1.1B
$11.2M
Q2 24
$1.0B
$39.3M
Q1 24
$1.1B
$61.6M
Total Assets
CERT
CERT
RYTM
RYTM
Q4 25
$1.6B
$480.2M
Q3 25
$1.5B
$506.9M
Q2 25
$1.5B
$372.7M
Q1 25
$1.6B
$386.7M
Q4 24
$1.6B
$392.3M
Q3 24
$1.5B
$363.6M
Q2 24
$1.5B
$381.8M
Q1 24
$1.5B
$258.7M
Debt / Equity
CERT
CERT
RYTM
RYTM
Q4 25
0.28×
Q3 25
0.28×
Q2 25
0.27×
Q1 25
0.27×
Q4 24
0.28×
Q3 24
0.28×
Q2 24
0.28×
Q1 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CERT
CERT
RYTM
RYTM
Operating Cash FlowLast quarter
$28.8M
$-25.4M
Free Cash FlowOCF − Capex
$27.8M
FCF MarginFCF / Revenue
26.8%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$94.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CERT
CERT
RYTM
RYTM
Q4 25
$28.8M
$-25.4M
Q3 25
$32.3M
$-26.6M
Q2 25
$17.8M
$-23.3M
Q1 25
$17.4M
$-40.4M
Q4 24
$49.4M
$-18.8M
Q3 24
$17.0M
$-25.2M
Q2 24
$9.8M
$-29.1M
Q1 24
$4.3M
$-40.7M
Free Cash Flow
CERT
CERT
RYTM
RYTM
Q4 25
$27.8M
Q3 25
$32.1M
Q2 25
$17.8M
Q1 25
$16.8M
Q4 24
$49.0M
Q3 24
$16.8M
Q2 24
$9.4M
Q1 24
$3.7M
FCF Margin
CERT
CERT
RYTM
RYTM
Q4 25
26.8%
Q3 25
30.7%
Q2 25
17.0%
Q1 25
15.8%
Q4 24
48.8%
Q3 24
17.7%
Q2 24
10.1%
Q1 24
3.8%
Capex Intensity
CERT
CERT
RYTM
RYTM
Q4 25
1.0%
Q3 25
0.2%
Q2 25
0.1%
Q1 25
0.6%
Q4 24
0.4%
Q3 24
0.2%
Q2 24
0.5%
Q1 24
0.6%
Cash Conversion
CERT
CERT
RYTM
RYTM
Q4 25
Q3 25
21.19×
Q2 25
Q1 25
3.66×
Q4 24
7.51×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons